Volume

Interactions between tumor microenvironment and resistance to transarterial and systemic treatments for HCC

Fibroblast growth factor receptor alterations and resistance mechanisms in the treatment of pediatric solid tumors

Acquired resistance to molecularly targeted therapies for cancer

PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an <i>in vitro</i> model of hepatocellular carcinoma

ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC

FGFR1 overexpression promotes resistance to PI3K inhibitor alpelisib in luminal breast cancer cells through receptor tyrosine kinase signaling-mediated activation of the estrogen receptor

Mechanisms of resistance to NAMPT inhibitors in cancer

Circular RNAs modulate cancer drug resistance: advances and challenges

Exosomal miR-92b-5p regulates N4BP1 to enhance PTEN mono-ubiquitination in doxorubicin-resistant AML

Research advances in natural sesquiterpene lactones: overcoming cancer drug resistance through modulation of key signaling pathways

Unraveling <i>BRAF</i> alterations: molecular insights to circumvent therapeutic resistance across cancer types

The epigenetic mechanisms involved in the treatment resistance of glioblastoma

Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing

Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinoma

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches

Exploring YAP1-related TIME in SCLC: implications for survival and treatment response to immuno-chemotherapy

Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance

Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers

Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression

Regulatory role of non-coding RNAs in 5-Fluorouracil resistance in gastrointestinal cancers

Integrative multi-omics analysis for identifying novel therapeutic targets and predicting immunotherapy efficacy in lung adenocarcinoma

Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment

Ferroptosis-related signaling pathways in cancer drug resistance

Strategies to combat cancer drug resistance: focus on copper metabolism and cuproptosis

The genetic architecture of bone metastases: unveiling the role of epigenetic and genetic modifications in drug resistance

Ivosidenib enhances cisplatin sensitivity in ovarian cancer by reducing cancer cell stemness

Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation

Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer

Advances in the application of patient-derived xenograft models in acute leukemia resistance

Antibody-drug conjugates in breast cancer: current resistance mechanisms and future combination strategies

MicroRNA-mediated autophagy regulation in thyroid cancer drug resistance

Integrated multi-omics profiling of immune microenvironment and drug resistance signatures for precision prognosis in prostate cancer

Modeling methods of different tumor organoids and their application in tumor drug resistance research

The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy

Actions for 0 selected articles

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/